High-dose cytosine arabinoside plus etoposide for acute myeloid leukaemia
Author Information
Author(s): P. Parikh, R. Powles, J. Treleaven, G. Helenglass, M. Gore, M. Rose, D. Talbot, S. Milan, C. Smith, R. Pinkerton, H. Aboud, J. Cavenagh, M. Rowley, T. McElwain, M. Hewetson
Primary Institution: Royal Marsden Hospital
Hypothesis
Can high-dose cytosine arabinoside and etoposide effectively treat newly diagnosed acute myeloid leukaemia?
Conclusion
High-dose cytosine arabinoside and etoposide are effective in inducing remission in patients with acute myeloid leukaemia.
Supporting Evidence
- 67% of patients entered remission using high-dose cytosine arabinoside and etoposide.
- Overall remission rate was 86.5% with a minimum follow-up of 90 days.
- Patients required less blood product and antibiotic support during treatment.
Takeaway
This study shows that a combination of two strong medicines can help many people with a type of blood cancer feel better.
Methodology
52 newly diagnosed patients with acute myeloid leukaemia received high-dose cytosine arabinoside and etoposide as induction chemotherapy.
Limitations
The study was conducted at a single center, which may limit the generalizability of the results.
Participant Demographics
28 males and 24 females, ages 6-56 years.
Want to read the original?
Access the complete publication on the publisher's website